Lamotrigin ”Nordic Prime 50 mg ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 114 | 非ジストロフィー性ミオトニー症候群 | 1 |
114. 非ジストロフィー性ミオトニー症候群
臨床試験数 : 13 / 薬物数 : 19 - (DrugBank : 5) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 10
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-003784-94-DK (EUCTR) | 20/01/2022 | 30/11/2021 | Which treatment are the best to reduce myotonia? | Treatment of Myotonia - Lamotrigine versus Namuscla | Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis MedDRA version: 20.1;Level: LLT;Classification code 10049841;Term: Myotonia congenital;System Organ Class: 100000004850 MedDRA version: 20.1;Classification code 10076440;Term: Hyperkalemic periodic paralysis;System Organ Class: 100000004850;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: Namuscla INN or Proposed INN: Mexiletine Trade Name: Lamotrigin ”Nordic Prime 25 mg INN or Proposed INN: LAMOTRIGINE Trade Name: Lamotrigin ”Nordic Prime 50 mg INN or Proposed INN: LAMOTRIGINE Trade Name: Lamotrigin ”Nordic Prime 100 mg INN or Proposed INN: LAMOTRIGINE | Rigshospitalet, department of Neurology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 32 | Phase 3 | Denmark |